Skip to main content
SpringerLink
Log in

OOP costs for PCSK9 protein inhibitors in USA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Davis LE, et al. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults. High Blood Pressure and Cardiovascular Prevention : 10 Jul 2020. Available from: URL: http://doi.org/10.1007/s40292-020-00399-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

OOP costs for PCSK9 protein inhibitors in USA. PharmacoEcon Outcomes News 858, 26 (2020). https://doi.org/10.1007/s40274-020-6999-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6999-7

Search

Navigation